| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 55.4 | 12.9 |
| Net income | -65.0 | -103.4 |
| EPS (diluted, $ a share) | $-1.09 | $-1.78 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +330.0% |
|---|---|
| Operating margin | -139.3% |
10-Q filed with the SEC, NASDAQ: AGIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Agios Pharmaceuticals, Inc.: key numbers
- Share price
- $30.15Close, Nov 16
- Market cap
- $1.8B
- Shares outstanding
- 59.81MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Agios Pharmaceuticals, Inc.
All →Agios Pharmaceuticals Financial Results
Agios Pharmaceuticals reported Q3 2026 financial results, highlighted by record quarterly net product revenue of $55.4 million, a four-fold increase year-over-year driven by the U.S. launch of AQVESME in thalassemia. The company ended the quarter with $907 million in cash and is preparing for a potential February 2027 FDA approval of mitapivat in sickle cell disease.
- Term
- Q3 2026
“The third quarter was a record for our product revenue, outperforming our entire 2025 total in just three months. This growth was driven by the U.S. commercial launch of AQVESME in thalassemia, where broadening demand is translating into a durable base of patients on therapy.”
Brian Goff, Chief Executive Officer
“This launch has built the commercial foundation for our largest indication opportunity with mitapivat – sickle cell disease. Our conviction in mitapivat for patients with sickle cell disease is grounded in the robust efficacy and safety data generated to date and we are launch-ready ahead of our PDUFA goal date of February 1, 2027.”
Brian Goff, Chief Executive Officer
Agios Pharmaceuticals CMO Sarah Gheuens Sells $296K of Stock
Sarah Gheuens, CMO, sold 7,866 shares of Agios Pharmaceuticals, Inc. at $37.69 a share, worth $296K in total on Oct 26, 2026. Shares held after the trade: 54,645 (-12.6%).
- Value
- $296K
- Shares
- 7,866
- Price
- $37.69
- Role
- CMO
- Holding change
- -12.6%
- Trade date
- Oct 26, 2026
Agios Pharmaceuticals CMO Sarah Gheuens Sells $74.6K of Stock
Sarah Gheuens, CMO, sold 1,989 shares of Agios Pharmaceuticals, Inc. at $37.52 to $37.53 a share (average $37.53) in 2 transactions, worth $74.6K in total between Oct 21, 2026 and Oct 22, 2026. Shares held after the trade: 54,645 (-0.9%).
- Value
- $74.6K
- Shares
- 1,989
- Average price
- $37.53
- Role
- CMO
- Holding change
- -0.9%
- Trade date
- Oct 21, 2026 to Oct 22, 2026